The Denials Aren’t Random. They’re Hardcoded.

The denials hitting independent specialty practices right now are not billing errors. They are not coding mistakes. They are not human judgment calls that went the wrong way. They are automated systems doing exactly what they were built to do.

Third Rail Intelligence ingests raw payer correspondence directly from practices during the review process: denial letters, EOBs, authorization records, internal claim inquiry responses and full appeal histories. Every document uploaded into the system across independent oncology, hematology, infusion, rheumatology, neurology, GI and ophthalmology practices in multiple states becomes part of a growing pattern catalogue mapped across payers, drug categories and denial types.

What our library shows is not a collection of individual billing disputes. It is a documented pattern of hard-coded automated barriers built into major commercial payer claims systems that are generating bulk denials against independent practices at scale.

These are not human errors, to be clear. Denials are rarely reviewed by a human unless or until escalated. They are structural roadblocks embedded, and the patterns we see suggest intentionally, in automated adjudication systems operated by Anthem, UnitedHealthcare, Cigna, Aetna and Blue Shield of California. When one of these automated systems generates a wrongful denial, it generates it across every claim processed under the same conditions. Every prior authorization submitted. Every practice. Every drug. Every patient that triggers the same automated logic. Simultaneously. Until someone identifies the specific failure and forces a correction.

When we have confronted payers and forced that correction, they pay. Quietly. Notably, they never acknowledge what was found. They never fix the underlying system. The barrier keeps running against every other practice that hasn’t identified it.

Here is what we are finding most consistently.

Fee schedule lag on new drug codes

Every time a drug receives FDA approval and a new J-code activates, the payer’s clinical policy system and fee schedule system update on different timelines. This is not limited to oncology. It runs across every practice administering high-cost biologics and specialty drugs: rheumatology, neurology, GI, hematology, ophthalmology and ambulatory infusion. Clinical policy adds the drug. The fee schedule misses the pricing entry. The automated claims system finds no pricing entry and rejects every claim for that code, across every practice billing it to that payer, until someone manually updates the fee schedule. No human reviews these denials unless we use the expedited appeal pathway.

We documented this precisely in a half-dozen practices on Datroway J9011 with Anthem following the January 2026 code activation. The same denial ran identically across every practice that administered the drug during the lag window, and it is not specific to Datroway. The claims system applies CO-96 to the drug line, stating no fee schedule entry exists, while applying CO-45 to the administration lines on the same claim, confirming a contracted fee schedule does exist. They cannot coexist. That contradiction sits on the same page of the EOB at every practice hit by this pattern. It appears across Anthem, UnitedHealthcare, Blue Shield, Cigna and Aetna.

Authorization to claims system disconnect

Anthem runs Carelon for utilization management. UnitedHealthcare runs Optum. Cigna runs Evicore. Each operates completely separately from the claims adjudication system. When the authorization system approves a drug for a specific NPI and the claims system denies that same NPI as non-contracted on the same date of service, that is two automated systems generating contradictory outputs on the same claim, with no human ever reconciling them. We have this documented precisely: an Anthem Carelon authorization for J9011 Datroway, and eleven days later, an Anthem grievances and appeals denial of the same drug, “doctor not contracted or billed incorrectly.” No human reviewed either determination.

At multi-location practices this compounds, because the two systems store NPI and location data differently. It runs across every claim where location routing created a mismatch.

Biosimilar transition code failures

When reference biologics transition to biosimilar J-codes, the fee schedule frequently fails to update all applicable biosimilar codes at the same time. The reference biologic pays. The biosimilar gets CO-96 denials because there is no pricing entry, despite the payer’s own formulary confirming biosimilar coverage. This ran across adalimumab, infliximab, bevacizumab, trastuzumab and rituximab biosimilar transitions at Anthem, UnitedHealthcare, Blue Shield and Aetna. Every practice that transitioned to biosimilar billing during those windows has this pattern in its write-off column.

Medical necessity denial without physician review

Automated claims systems generate medical necessity denials with no licensed physician reviewer ever looking at the clinical record. In California this violates Health and Safety Code 1367.01, which requires licensed clinician involvement in utilization review decisions, and analogous utilization review statutes exist in most states. The claims system pattern-matches on diagnosis codes and treatment line indicators and generates the denial automatically.

What makes these cases particularly recoverable is the contradiction with the payer’s own authorization. In multiple cases in our library, the payer’s authorization system approved the drug with zero clinical documentation while the claims system denied it for the same patient, citing medical necessity. The payer approved it through one automated system and denied it through another, with no physician involved in either determination. That position does not survive Independent Medical Review, which we use when necessary. Which is why they pay quietly when it is properly documented.

Step therapy denial without exception evaluation

Payers widely apply step therapy requirements across high-cost specialty drugs without evaluating whether the patient meets exception criteria. Federal step therapy protections and state statutes in most commercial insurance markets require exception criteria to be evaluated before a step therapy denial is issued: contraindication to the required first-step drug, prior treatment failure, clinical urgency, physician judgment. The automated system ignores all of it and generates bulk denials across every patient whose request triggers the step therapy algorithm. No human review here either.

Every one of these denials generated without documented exception evaluation is a violation of statute. We have raised this multiple times with this group of payers during the appeal process, and as of yet not one has responded with an acknowledgement in writing. This is running across Anthem, UnitedHealthcare, Blue Shield and Aetna on oncology, rheumatology, neurology and GI drugs right now.

What these patterns share

Every one was generated by an automated system with no human review. Every one repeats identically across every claim it touches, because the decisions are effectively hard-coded before any authorization or appeal your practice submits, and these systems process thousands of submissions every day, in waves. And every time we have properly documented one and forced the payer to confront its own record, it has paid. Without comment. Without fixing the system.

The barriers are still running. The abandoned claims at practices and infusion centers across multiple states contain a substantial sum of recoverable money. It’s worth looking at what you’re sitting on. The answer is in the cumulative correspondence, not the denial letters themselves.